Bright Minds Biosciences (TSE:DRUG) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Bright Minds Biosciences has announced promising preclinical results for its compound BMB-201, which showed similar pain relief efficacy to morphine without the associated dependency risks. This development is a significant step in providing non-opioid alternatives for neuropathic pain management, with plans to advance into clinical trials.
For further insights into TSE:DRUG stock, check out TipRanks’ Stock Analysis page.